ABSI Absci Corporation NASDAQ $2.86 on 19 Mar 2026: earnings Mar 24 could shift targets

ABSI stock trades intraday at $2.86 on the NASDAQ in the United States on 19 Mar 2026, and investors are focused on Absci Corporation’s earnings scheduled for 24 Mar 2026. Volume is elevated at 6,821,423 shares versus an average of 3,660,752, showing increased trading interest ahead of the report. Key fundamentals include EPS -0.91, PE -3.14, and a market cap of $430,062,579. We use Meyka AI-powered market analysis platform outputs and public analyst notes to highlight what could move the stock at the upcoming release.

Earnings timeline and expectations for ABSI stock

Absci’s next earnings announcement is scheduled for 24 Mar 2026 (post-close). Investors will watch revenue trends, partnership deal flow and any updates to collaboration timelines. One central metric to monitor is R&D cadence, given Absci’s high R&D-to-revenue ratio of 26.45%, which drives near-term cash burn and long-term product value. Management commentary on partner programs or new licensing could swing sentiment and shifts between the current trading range of $2.84–$3.07.

Recent performance and financials for Absci Corporation (ABSI stock)

ABSI opened today at $2.92, down from a previous close of $3.03, and trades below its 200-day average of $3.08 but near its 50-day average of $2.88. The company reports EPS -0.91 and negative margins: net profit margin -40.71% and operating margin -42.29%, highlighting continued investment-stage losses. Liquidity metrics are stronger: cash per share $1.06 and current ratio 5.89, which should support operations through near-term development milestones.

Analyst ratings and price targets for ABSI stock

Wall Street coverage is mixed but tilted positive: five Buy, one Hold and one Sell, with a consensus target of $7.66 and targets ranging from $4.32 (Morgan Stanley) to $8.00 (HC Wainwright). Needham carries a $7.00 target. That consensus implies potential upside from the current $2.86. See recent coverage and the consensus forecast on MarketBeat for further detail MarketBeat forecast. Institutional filings show sizable stakes from ARK and State Street, reinforcing analyst attention MarketBeat news on filings.

Technical and liquidity signals for ABSI stock

Momentum indicators are mixed: RSI 54.93 suggests neutral strength while ADX 27.30 signals a firming trend. MACD sits at -0.05 with a histogram of 0.05, and ATR is 0.22, implying moderate intraday swings. On-balance volume is negative -2,190,392, but today’s relative volume 1.85 shows heavy interest. Traders should watch the Bollinger band upper at 2.99 and lower at 2.28 for breakout or reversal clues around earnings.

Meyka AI rates ABSI with a score out of 100 and forecast for ABSI stock

Meyka AI rates ABSI with a score out of 100: 65.29 / 100 — Grade B, Suggestion: HOLD. This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a yearly price of $2.55, a quarterly projection of $2.38 and a monthly projection of $0.98. Compared with the current price $2.86, the yearly projection implies an implied change of -10.74%. Forecasts are model-based projections and not guarantees.

Risks and opportunities for ABSI stock

Opportunities include Absci’s Integrated Drug Creation platform and large institutional ownership of 52.05%, plus recent insider buying of 100,000 shares by Andreas Busch at $2.29, which signals management conviction. Risks include persistent negative margins, a high price-to-sales ratio ~153.04, and volatile trading (beta 2.12). CEO selling of 26,761 shares at $2.99 is a note for shareholders; monitor insider flow and partnership milestones after the earnings release.

Final Thoughts

Key takeaways for ABSI stock ahead of the 24 Mar 2026 earnings report: Absci trades at $2.86 on NASDAQ with elevated volume and mixed technicals, leaving price sensitive to execution updates. Analyst targets range from $4.32 to $8.00 with a consensus near $7.66, implying significant upside if management delivers partnership progress. Meyka AI’s forecast model projects a yearly price of $2.55, implying -10.74% from the current price; this reflects a conservative, model-driven view focused on near-term fundamentals. Our Meyka AI grade is 65.29 (B, HOLD), which balances growth potential and execution risk. Traders should watch pre- and post-earnings guidance on collaborations, R&D pacing and cash usage. Forecasts and grades are projections and not investment guarantees; use them with your own research and risk management.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.